Subic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Subic

Understanding Subic

Subic is a pharmacological treatment utilized primarily in the management of opioid dependence. It is a combination medication consisting of two active ingredients: buprenorphine and naloxone. This combination is designed to assist individuals in reducing or quitting their use of heroin or other opiate drugs.

Composition and Mechanism

The two components of Subic serve distinct roles in the treatment process:

  • Buprenorphine: This ingredient is classified as a partial opioid agonist. It works by attaching to the same receptors in the brain as other opioids. However, it produces less physical dependence and a weaker euphoric effect. By occupying these receptors, it helps to alleviate cravings and diminish withdrawal symptoms.
  • Naloxone: This ingredient is an opioid antagonist. Its primary purpose in the formulation is to discourage misuse. If the medication is used as intended, the naloxone component has minimal effect.

Clinical Purpose

Subic is employed as part of a comprehensive maintenance treatment program. The objective of such programs is to provide medical stabilization for individuals transitioning away from illicit opioid use or prescription opioid misuse. The medication is typically integrated into a broader recovery plan that includes counseling and psychological support to address the behavioral aspects of dependence.

Treatment Phases

The use of Subic generally involves different phases of care:

  1. Induction: The initial stage where the individual transitions from the opioid of misuse to the medication under medical supervision.
  2. Stabilization: The phase where the dosage is adjusted until the individual experiences a significant reduction in cravings and no longer experiences withdrawal symptoms.
  3. Maintenance: The long-term phase where the individual remains on a steady dose while focusing on therapy and social reintegration.

What side effects are possible with Subic?

Possible Side Effects and Safety Information

The regulatory safety documentation for Subic (Meloxicam) defines the range of possible adverse reactions and associated safety limitations. The overall safety profile is primarily structured around the potential for two high-level, serious adverse reactions: Cardiovascular (CV) Thrombotic Events and Gastrointestinal (GI) Adverse Events.


Official Adverse Reaction Scope

Classification Examples of Reactions Description of Risk
Serious Adverse Reactions Myocardial Infarction, Stroke, GI Bleeding, Ulceration, Perforation Can be fatal and may occur at any time during treatment, sometimes without warning symptoms. The CV risk may increase with the duration of use.
Most Common Reactions Diarrhea, Dyspepsia (Indigestion), Upper Respiratory Tract Infections, Headache These events are reported by regulatory authorities as occurring in at least 5% of patients and more frequently than placebo in clinical trials.
System-Organ Classes Gastrointestinal, Cardiovascular, Renal/Urinary, Hepato-biliary, Skin/Immune System Adverse effects are grouped into these physiological categories, with a documented potential for toxicity in the kidneys and liver.

Population and Time-Related Safety Patterns

Specific regulatory notes highlight that older adults (geriatrics) are at a greater risk for serious GI events and require cautious use. Avoidance is mandated in late-term pregnancy (after 30 weeks gestation) due to the risk of premature closure of the fetal ductus arteriosus.

Regulatory restrictions mandate that the medicine is contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery. The concurrent use with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is generally not recommended due to increased risk of adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this medicine may initially present with documented clinical signs, including nausea, vomiting, drowsiness, and epigastric pain. A suspected substantial overdose or severe poisoning carries the risk of progressing to life-threatening systemic consequences. These officially documented severe outcomes include acute renal failure, hepatic dysfunction, respiratory depression, convulsions, coma, and cardiovascular collapse. Anaphylactoid reactions are also recognized as a potential severe manifestation.

Immediate medical attention is required for suspected substantial overdose or for the occurrence of any severe systemic effects. According to regulatory documents, no specific antidote is known for this overdose. Management is based on providing symptomatic and supportive care.

Officially described supportive measures include the recommendation for administering activated charcoal within 1 to 2 hours of ingestion, which may be repeated for substantial overdose. Cholestyramine is also noted as a measure that can accelerate drug clearance. Regulatory information indicates that forced diuresis or hemodialysis may not be useful due to the drug’s high protein binding.

Therapeutic Uses of Subic

What Subic Treats: Main Uses and Benefits

Subic may be part of symptomatic management for symptoms associated with chronic inflammatory joint conditions. It is applied across therapeutic domains where additional symptomatic support is needed, addressing conditions characterized by periods of heightened symptoms, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also considered relevant in specialized clinical settings for the management of Juvenile Idiopathic Arthritis (JIA) in children 2 years of age and older.

The medication is relevant for easing symptoms related to physical discomfort and functional strain, which may include persistent pain, joint swelling, and functional stiffness. It is applied in scenarios where additional management of discomfort is required.

“It contributes to improved comfort during periods of heightened symptoms and may assist with coping more steadily with symptom fluctuations.”

This usage supports the patient during difficult episodes by providing supportive relief when symptoms are more noticeable.

Quick Fact: Relief for Key Symptoms
Pain Is relevant for easing symptoms related to physical discomfort.
Stiffness May assist with maintaining functional stability.
Swelling Is applied in addressing symptoms related to inflammatory states.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Subic

Official regulatory guidelines define the populations permitted to use Subic (Meloxicam) and those for whom it is strictly prohibited or restricted. Use is generally approved for adults with Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS).

Classification Population or Condition
Use Allowed (Conditional) Children 2 years of age and older for Juvenile Idiopathic Arthritis (JIA). Older adults (ge 65 years) require caution [1.5].
Not Recommended/Avoid Use Patients with severe renal impairment or advanced renal disease. Patients with severe hepatic impairment or severe heart failure. Pregnant women between 20 and 30 weeks gestation [1.8].
Contraindicated (Prohibited) Patients with known hypersensitivity to Meloxicam or a history of NSAID-sensitive asthma. Individuals receiving treatment for pain after CABG surgery. Patients with active peptic ulcerations, bleeding disorders, or severe, uncontrolled CHF (NYHA II–IV). Pregnant women starting at 30 weeks gestation and later [1.1, 1.8].

The eligibility profile is structured by absolute prohibitions—such as known allergies and post-CABG use—and conditional restrictions related to age and organ function status. This framework establishes the necessary patient boundaries, requiring strict avoidance in cases of severe organ impairment or late pregnancy [1.8].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Subic (Meloxicam) has documented interactions that fall into two main regulatory categories: pharmacodynamic effects and pharmacokinetic modifications. The product information describes specific restrictions and outcomes when combined with other medicines or substances.

Interaction-Related Restrictions

Co-administration with other Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is generally contraindicated or should be avoided due to the documented increase in the risk of serious gastrointestinal events. Subic is also contraindicated for the management of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery. Use of Aspirin at analgesic or anti-inflammatory doses is not generally recommended as it further increases gastrointestinal risk. Alcohol (Ethanol) consumption is officially advised against, as this substance increases the risk of stomach bleeding.

Documented Interaction Outcomes

Interaction Type Interacting Substance / Category Official Documented Outcome
Increased Bleeding/GI Risk Oral Anticoagulants, Antiplatelet Agents, SSRIs/SNRIs, Oral Corticosteroids Increased risk of bleeding complications or ulceration.
Altered Drug Levels Lithium and Methotrexate Co-administration leads to increased plasma levels of these substances due to reduced clearance.
Diminished Effects Diuretics and ACE Inhibitors/ARBs May diminish the natriuretic and antihypertensive effects of these medicines.
Altered Clearance Cholestyramine Leads to accelerated Meloxicam clearance.

The official profile emphasizes additive risks with other blood thinners and GI irritants, as well as pharmacokinetic interactions that modify drug exposure. In high-risk populations, such as the elderly or those with renal impairment, combining Meloxicam with ACE Inhibitors or ARBs may result in a deterioration of renal function. This structure defines the mandatory restrictions and constraints for co-administration.

Mechanism of Action

The biological action of Subic (Meloxicam) is defined by its ability to interfere with the chemical cascade that regulates eicosanoid production and subsequent modulation of nociceptive and inflammatory pathways.

Targeted COX-2 Enzyme Inhibition

Meloxicam functions as an inhibitor with a strong preference for the Cyclooxygenase-2 ( COX-2) enzyme , the inducible isoform whose expression is upregulated during specific physiological responses. This inhibition reduces the enzyme’s catalytic function in initiating the synthesis of pro-inflammatory chemical messengers.

Disruption of the Prostaglandin Synthesis Pathway

By blocking the enzymatic action of COX-2, the mechanism disrupts the entire Prostaglandin Synthesis Cascade, leading to a measurable reduction in mediators like PGE2. This systemic reduction in signaling molecules decreases the sensitization threshold of peripheral nociceptors and simultaneously inhibits the central prostaglandin synthesis responsible for altering the hypothalamic set point, which constitutes the mechanism of nociceptive pathway modulation and central thermoregulation.

Mechanistic Limitations of Selectivity

The preferential inhibition of COX-2 is concentration-dependent and applies only at lower plasma concentrations. At higher concentrations, the drug's inhibitory activity against the constitutive COX-1 enzyme significantly increases, demonstrating a dose-dependent functional interaction with both enzyme isoforms.

Dosage and Administration Information

Official Administration Guidelines

Subic is officially administered via oral and intravenous (IV) injection routes, with the governing principle being the use of the lowest effective dose for the shortest duration consistent with treatment goals. All approved oral formulations, including tablets and suspension, are intended for once daily use and may be taken without regard to the timing of meals.

Dosing and Frequency

Regimen Dose and Frequency Maximum Daily Dose
Adult Oral Start at 7.5 mg once daily; may increase if needed. 15 mg
IV Injection 30 mg once daily. 30 mg

Special Administration Rules

Administration for specific populations requires explicit dose modification based on official labeling. For patients undergoing hemodialysis, the maximum daily oral dose is 7.5 mg. For the treatment of Juvenile Idiopathic Arthritis (JIA) in children two years of age and older, the dose is weight-based (0.125 mg/kg), with a maximum daily limit of 7.5 mg.

Procedurally, the oral suspension must be shaken gently before measuring a dose. The IV formulation must be given as an intravenous bolus injection over a specific duration, typically 15 seconds, and patients must be well hydrated before administration. If a dose is missed, the standard procedure is to skip the missed dose and continue with the regular schedule, without taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Subic


Evidence for Use in Osteoarthritis (OA)

Research exploring the use of Subic (Meloxicam) in Osteoarthritis (OA) is primarily drawn from short-term, randomized controlled trials (RCTs) and systematic reviews. The studies were designed to measure changes in symptoms in adults with OA, typically affecting the hip or knee. The trials explored outcomes related to physical discomfort, measuring changes in pain intensity and assessing physical limitations through functional indices. Studies report patterns that were measured in the observed populations during the research. Most research exploring symptomatic change focused on short observation periods, and the research explored short-term changes in discomfort.


Evidence for Use in Rheumatoid Arthritis (RA)

Research examined Subic (Meloxicam) for signs and symptoms related to Rheumatoid Arthritis (RA) in adults. These studies frequently involved comparative randomized trials against other established medications. Studies examined outcomes related to joint discomfort by measuring the number of tender and swollen joints and assessing the duration of morning stiffness. Researchers also evaluated whether patients reached specific improvement benchmarks, such as the ACR 20 response criteria. Findings show patterns that were observed over the duration of the trials. The research is primarily focused on measuring changes in signs and symptoms rather than altering the course of the underlying disease progression.


Evidence for Use in Juvenile Idiopathic Arthritis (JIA)

Research examined the application of Subic (Meloxicam) in a specific pediatric population—children aged 2 to 16 years with Juvenile Idiopathic Arthritis (JIA). The studies were often active-controlled comparative trials. These studies monitored specific pediatric outcomes, including the ACR Pediatric 30 response and functional status scales, which are patient-reported outcomes describing perceived discomfort. The sample sizes were modest in the core clinical trials compared to adult studies. This means the evidence base provides information on short-term comparative performance, but there is limited information for long-term outcomes beyond one year in children.


Overall Research Gaps and Areas of Uncertainty

While a substantial body of research exists, a key limitation is that the results apply only to the populations studied, meaning findings describe group patterns, not personal outcomes. The follow-up durations were limited for sustained symptomatic observations over multiple years in chronic conditions. Long-term effects are not fully established based on the primary efficacy measures, and research exploring the durability of symptomatic observations beyond the typical one-year mark is still emerging.

Frequently Asked Questions (FAQ)

Common questions about Subic (FAQ)

Q: How quickly does Subic usually start to work?

According to official documentation, it may take time to experience the full effects of Subic (Meloxicam). Regulatory information indicates that the maximum anti-inflammatory effect and full pain-relieving benefit may be observed after several days to a week of consistent use. When administered as an intravenous (IV) injection, the relief of pain may begin sooner, potentially within 10 to 15 minutes.


Q: Can Subic cause weight changes?

Regulatory documents indicate that fluid retention, also known as edema, is a reported possible side effect of this medication. Weight gain has been mentioned in official reports as a less common or rare side effect, typically affecting a small percentage of patients in clinical trials.


Q: Is Subic generally considered safe for older adults?

Official documentation states that older adults, defined as those aged 65 years and older, should use Subic with caution. Official documentation notes that this population has a documented greater potential risk for serious adverse effects, including those involving the digestive system, kidneys, and heart.


Q: Are there any vitamins or supplements that are known to interact with Subic?

Official patient information often advises caution with certain supplements, as some may influence the risk of bleeding. For example, co-administration with supplements like Ginkgo bilbo has been noted to increase the risk of bleeding complications. Additionally, using potassium supplements may interact with Subic and potentially lead to elevated potassium levels in the body.


Q: Is it true that Subic can affect sleep?

Yes, sleep disturbances are listed in regulatory sources as possible adverse effects. Both insomnia (difficulty sleeping) and generalized symptoms like sleepiness or fatigue have been reported by patients in clinical studies. When sleep changes are experienced, individuals should refer to their healthcare provider for guidance.


Q: How long does Subic typically stay in the body after stopping use?

Subic has a relatively long elimination half-life, which means it takes a while for the body to process it. The official pharmacokinetics data indicates that the medicine is typically eliminated from the body within approximately 3 to 5 days after the last dose.


Q: Are the long-term effects of using Subic well-studied?

According to regulatory research summaries, the core clinical trials had limitations on the duration of follow-up for chronic conditions. This means that while much is known about short-term effects, the definitive long-term effects, particularly beyond one year, are officially noted as not fully established by the primary efficacy measures.


Q: Can Subic affect the results of lab tests?

Regulatory labeling and official patient information generally do not indicate that Subic is known to interfere with or alter the results of routine clinical laboratory tests. However, like many medicines, it may influence results related to kidney and liver function, which is information often reviewed by healthcare providers.


Q: Does Subic have a potential for dependency or withdrawal symptoms?

Subic (Meloxicam) is not classified as a controlled substance and has no associated potential for addiction. However, abruptly stopping the medication, especially after long-term use, may be associated with a return of the underlying symptoms of pain and inflammation.


Q: Are there any food restrictions or dietary changes needed with Subic?

Official product information advises against the consumption of alcohol due to an increased risk of stomach bleeding. Additionally, some official patient resources recommend caution regarding high consumption of grapefruit or grapefruit juice, as this may influence the drug's levels in the body.


Q: What is the typical duration of treatment with Subic?

Subic is officially indicated for the management of signs and symptoms related to chronic conditions, such as Osteoarthritis and Rheumatoid Arthritis. Therefore, its use is typically considered for long-term treatment and management, based on clinical trial designs.


Q: What does official research say about the effectiveness of Subic?

Clinical trials reviewed by regulatory bodies found measured improvements in the specific signs and symptoms studied. These measured benefits include reductions in pain intensity, decreased joint swelling, and meeting specific disease improvement benchmarks like the ACR response criteria.


Q: Is it normal to feel tired or dizzy when starting Subic?

Official regulatory documents list both dizziness and fatigue/tiredness among the possible adverse effects. These are reported as common side effects that occurred in a measurable percentage of patients during clinical trials.


Q: Can Subic cause sun sensitivity?

Yes, regulatory patient documentation notes that this medicine may increase your sensitivity to the sun. Patient information typically describes measures like using protective clothing and sunscreen when spending time outdoors due to this potential.


Q: Is Subic considered a controlled substance?

Subic (Meloxicam) is a prescription-only (Rx) medication, meaning it cannot be purchased without authorization from a healthcare provider. However, it is not classified as a controlled substance under federal law, which applies to drugs with a high risk of dependency or abuse.


Q: Does Subic interact with herbal remedies like St. John's Wort?

Regulatory warnings for this class of medicine generally advise caution regarding co-administration with various herbal products. Since some herbs, such as St. John's Wort and Ginkgo biloba, can affect bleeding risk or drug metabolism, they are typically mentioned in official drug interaction databases.


Q: What information is available about pediatric studies for Subic?

Research is available for children aged 2 to 16 years with Juvenile Idiopathic Arthritis (JIA). These studies often compared Subic against other active medicines, but official data notes that the number of children studied was limited and long-term follow-up beyond one year is not extensive.


Q: Is Subic meant for short-term or long-term use?

Subic is officially indicated for managing the signs and symptoms of chronic conditions like Osteoarthritis and Rheumatoid Arthritis. Therefore, it is commonly used for the purposes of long-term treatment and management.

How should Subic be stored and disposed of?

Prescription medicines must be stored and disposed of according to strict official guidelines to prevent accidental exposure, especially in children and pets. This product must be kept in its original, secured packaging and stored in a location inaccessible to children and pets at all times. Controlled medications require additional security, often mandating storage in a locked cabinet or drawer.

Storage & Disposal Requirements

Storage Condition Requirement
Temperature Store as specified on the prescription label; must maintain the drug's quality.
Child Protection Keep out of reach of children and pets. Securely lock the container.
Stability Do not use past the expiration date on the label. Discard immediately after any in-use stability period expires.
Disposal The best method is a drug take-back program or a mail-back envelope. Do not flush the medication unless it is specifically listed on the FDA's flush list. If disposal in household trash is necessary, first mix the drug with an undesirable, inedible substance like used coffee grounds or cat litter, place the mixture in a sealed container, and then discard.

All disposal must comply with applicable federal, state, and local regulations. Scratch out all personal information on the label before disposing of the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Subic found in:

A-Z Index: